AI Stock Memo: ARVN - Arvinas - RankAlpha

ARVN

Rating neutralAI MemoPost-earnings T+3

Arvinas

As of 2026-05-15/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ARV-102 regulatory feedback and added biomarker data are the key 2H26 pipeline readout • 2026-08-13

Expected move: +22%

Biggest risk

The bear read is that Q1 revenue fell to $15.6 million from $188.8 million a year earlier, with the company attributing the drop mainly to prior vepdegestrant program-cost estimate changes, so near-term fundamentals remain noisy and dependent on collaboration accounting rather than a clean commercial ramp [#8-K-2026-05-12]. Sell-side follow-through exists but remains thin and does not remove the need for several 2H26 execution wins.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

The post-print bull read is that first-in-class PROTAC approval plus the planned Rigel handoff lets Arvinas redirect focus toward ARV-102, ARV-806 and ARV-393 while cash runway guidance extends into 2H28 [#8-K-2026-05-12]. Secondary reaction was constructive: StockAnalysis showed BofA raising its target to $16 from $14, BTIG to $18 from $16, and Barclays to $20 from $18 after the update.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-15

Base target

$11

p=45%

Bull target

$16

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

VEPPANU out-licensing close with Rigel could crystallize near-term economics
Multiple 2026 early-stage oncology readouts can test whether Arvinas remains a platform story
The post-print bull read is that first-in-class PROTAC approval plus the planned Rigel handoff lets Arvinas redirect focus toward ARV-102, ARV-806 and ARV-393 while cash runway guidance extends into 2H28 [#8-K-2026-05-12].

BearKey bullets

ARV-102’s next step in PSP is explicitly pending FDA feedback, so delay or narrower trial scope would pressure one of the cleanest 2H26 catalysts.
Cash, cash equivalents and marketable securities fell to $614.9 million from $685.4 million in one quarter, with $67.5 million of operating cash use, so runway is solid but burn remains meaningful [#8-K-2026-05-12].
Most pipeline value still rests on early-stage oncology and neurology programs where initial data can be hard to translate into later clinical success.

WatchKey bullets

ARV-102 regulatory feedback and added biomarker data are the key 2H26 pipeline readout

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $11 (p=45%)

Bull/Bear spread: +73% / -28%

Vs latest close: Bull +73% · Base +22% · Bear -28%

Scenario probabilities

Bull Target: $16 (p=30%)Base Target: $11 (p=45%)Bear Target: $7 (p=25%)

Commentary

T+3 earnings follow-up reads mixed-to-constructive rather than decisively bullish. The company source delivered an approval-plus-pipeline update and reaffirmed runway into 2H28 [#8-K-2026-05-12], while secondary post-print coverage showed several upward target revisions. Even so, the tape still looks unstable: StockAnalysis showed ARVN at $9.42 on May 14, 2026, down 4.56% that day, which suggests investors have not fully capitalized the approval and licensing news. Analyst revision breadth remains limited, and no reliable social signal was provided in the packet, so this stays a cautious monitoring setup.

As of 2026-05-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

VEPPANU out-licensing close with Rigel could crystallize near-term economics
Multiple 2026 early-stage oncology readouts can test whether Arvinas remains a platform story

Scenarios

Bull Target (Scenario probability)

$16 / p=30% prob

Base Target (Scenario probability)

$11 / p=45% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Price $9 as of 2026-05-29

Nearest Scenario: Base (∆ 22%)

Targets vs latest close: Bull +73% · Base +22% · Bear -28%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-13
ARV-102 regulatory feedback and added biomarker data are the key 2H26 pipeline readout
Management guided to a Phase 1b PSP start for ARV-102 upon FDA clearance and to additional Parkinson’s biomarker data in 2H26 after reporting >50% LRRK2 degradation in CSF and biomarker modulation in Phase 1; this is the clearest program-level value inflection beyond VEPPANU [#8-K-2026-05-12].
Prob 55.00% • Move 18.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

VEPPANU out-licensing close with Rigel could crystallize near-term economics
2026-08-13
Arvinas said VEPPANU was approved, then licensed with Pfizer to Rigel, with closing still subject to consents and HSR clearance; the same earnings update also highlighted VEPPANU’s NCCN inclusion, making deal close and early commercialization optics the nearest tangible post-approval checkpoint [#8-K-2026-05-12].
Prob 70% • Move 12% • Priced-in 45%

Long-term Catalysts

Months to a year

Multiple 2026 early-stage oncology readouts can test whether Arvinas remains a platform story
2027-05-15
The company said ARV-806 should enter dose expansion and produce initial 2026 data, ARV-393 should post updated Phase 1 data in 2H26, and ARV-6723 is planned to enter Phase 1 in mid-2026; success would broaden the story beyond vepdegestrant, while slippage would reinforce a monitoring stance [#8-K-2026-05-12].
Prob 50% • Move 22% • Priced-in 25%

Risks

ARV-102’s next step in PSP is explicitly pending FDA feedback, so delay or narrower trial scope would pressure one of the cleanest 2H26 catalysts.
Cash, cash equivalents and marketable securities fell to $614.9 million from $685.4 million in one quarter, with $67.5 million of operating cash use, so runway is solid but burn remains meaningful [#8-K-2026-05-12].
Most pipeline value still rests on early-stage oncology and neurology programs where initial data can be hard to translate into later clinical success.
Q1 revenue was volatile and down sharply year over year because of collaboration-accounting effects, leaving near-term financial optics weak even after approval [#8-K-2026-05-12].
VEPPANU’s transfer to Rigel still requires consents and HSR-related clearance, so timing or economics slippage could blunt the perceived benefit of out-licensing.

Peers

Symbol	Summary
ACHV	Packet peer only; like ARVN it is a small-cap biotech whose equity can swing on a narrow set of clinical and regulatory milestones, but it is not a direct modality or indication peer.
AQST	Packet peer only; useful mainly as another event-driven small-cap biotech comp with execution and financing sensitivity rather than as a direct PROTAC or oncology-development peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-15